- $25.67m
- -$11.76m
- 38
- 44
- 56
- 43
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.69 | ||
Price to Tang. Book | 0.69 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -19.6% | ||
Return on Equity | -13.57% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.
Directors
- Robert Conway NEC (67)
- Michael Bristow CEO (76)
- C. Jeffrey Dekker CFO (56)
- Thomas Keuer COO (62)
- Christopher Ozeroff SVP (62)
- Christopher Graybill VPR
- Linda Grais IND (64)
- Anders Hove IND (55)
- Daniel Mitchell IND (64)
- Raymond Woosley IND (78)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 16th, 2004
- Public Since
- July 21st, 2000
- No. of Shareholders
- 13
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 14,501,143
- Address
- Suite 430, 8001 Arista Place, BROOMFIELD, 80021
- Web
- https://arcabio.com/
- Phone
- +1 7209402200
- Auditors
- KPMG LLP
Upcoming Events for ABIO
Q2 2024 ARCA Biopharma Inc Earnings Release
Similar to ABIO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 18:02 UTC, shares in ARCA biopharma are trading at $1.77. This share price information is delayed by 15 minutes.
Shares in ARCA biopharma last closed at $1.77 and the price had moved by -12.81% over the past 365 days. In terms of relative price strength the ARCA biopharma share price has underperformed the S&P500 Index by -33.85% over the past year.
The overall consensus recommendation for ARCA biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ARCA biopharma does not currently pay a dividend.
ARCA biopharma does not currently pay a dividend.
ARCA biopharma does not currently pay a dividend.
To buy shares in ARCA biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.77, shares in ARCA biopharma had a market capitalisation of $25.67m.
Here are the trading details for ARCA biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ABIO
Based on an overall assessment of its quality, value and momentum ARCA biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARCA biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -27.03%.
As of the last closing price of $1.77, shares in ARCA biopharma were trading -5.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ARCA biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ARCA biopharma's management team is headed by:
- Robert Conway - NEC
- Michael Bristow - CEO
- C. Jeffrey Dekker - CFO
- Thomas Keuer - COO
- Christopher Ozeroff - SVP
- Christopher Graybill - VPR
- Linda Grais - IND
- Anders Hove - IND
- Daniel Mitchell - IND
- Raymond Woosley - IND